FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224871294> ?p ?o ?g. }

• W4224871294 endingPage "104010" @default.
• W4224871294 startingPage "104010" @default.
• W4224871294 abstract "Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR+/HER2- metastatic breast cancer (mBC). In this prospective study, we investigate the impact of CDK4/6i on the immune profile of patients with HR+/HER2- mBC.Immune cell subsets were analysed using flow cytometry of peripheral blood mononuclear cells (PBMCs) isolated from patients with HR+/HER2- mBC, both before and during treatment. Regulatory T cells (Tregs) were identified using the markers CD4, CD25, CTLA4, CD45RA, and intracellular FOXP3. Monocytic and polymorphonuclear myeloid-derived suppressor cells (M-MDSCs and PMN-MDSCs) and other immune populations were analysed using CD45, CD14, CD66b, CD11c, HLA-DR, CD3, CD8, CD28, CD137, PD1, CD45RA, CCR7, and Ki67.The percentage of circulating Tregs and M/PMN-MDSCs was significantly downregulated from baseline during CDK4/6i-treatment (p<0.0001 and p<0.05, respectively). In particular, the effector Treg subset (CD4+CD25+FOXP3highCD45RA-) was strongly reduced (p<0.0001). The decrease in Treg levels was significantly greater in responder patients than in non-responder patients. Conversely, CDK4/6i treatment was associated with increased levels of CD4+ T cells and anti-tumour CD137+CD8+ T cells (p<0.05).CDK4/6i treatment results in downregulation of Tregs, M-MDSCs, and PMN-MDSCs, thus weakening tumour immunosuppression. This decrease is associated with response to treatment, highlighting the importance of unleashing immunity in cancer treatment efficacy. These results suggest a novel mechanism of immunomodulation in mBC and provide valuable information for the future design of novel treatments combining CDK4/6i with immunotherapy in other cancer settings.Sapienza University of Rome." @default.
• W4224871294 created "2022-04-27" @default.
• W4224871294 creator A5019444838 @default.
• W4224871294 creator A5025723323 @default.
• W4224871294 creator A5036426179 @default.
• W4224871294 creator A5042989547 @default.
• W4224871294 creator A5058082424 @default.
• W4224871294 creator A5065468471 @default.
• W4224871294 creator A5066692929 @default.
• W4224871294 creator A5067780934 @default.
• W4224871294 creator A5069311489 @default.
• W4224871294 creator A5077736286 @default.
• W4224871294 creator A5089554789 @default.
• W4224871294 creator A5091286114 @default.
• W4224871294 date "2022-05-01" @default.
• W4224871294 modified "2023-10-09" @default.
• W4224871294 title "Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response" @default.
• W4224871294 cites W1519521580 @default.
• W4224871294 cites W1596456096 @default.
• W4224871294 cites W1636854345 @default.
• W4224871294 cites W1757407923 @default.
• W4224871294 cites W1908442436 @default.
• W4224871294 cites W1977035973 @default.
• W4224871294 cites W1984245506 @default.
• W4224871294 cites W2007631222 @default.
• W4224871294 cites W2028263975 @default.
• W4224871294 cites W2038918212 @default.
• W4224871294 cites W2050714058 @default.
• W4224871294 cites W2051269613 @default.
• W4224871294 cites W2060672294 @default.
• W4224871294 cites W2063667712 @default.
• W4224871294 cites W2091041835 @default.
• W4224871294 cites W2116159991 @default.
• W4224871294 cites W2117692326 @default.
• W4224871294 cites W2155263737 @default.
• W4224871294 cites W2155609574 @default.
• W4224871294 cites W2167350292 @default.
• W4224871294 cites W2171852242 @default.
• W4224871294 cites W2320248812 @default.
• W4224871294 cites W2328176404 @default.
• W4224871294 cites W2344037260 @default.
• W4224871294 cites W2373606074 @default.
• W4224871294 cites W2401056916 @default.
• W4224871294 cites W2491062142 @default.
• W4224871294 cites W2528767298 @default.
• W4224871294 cites W2552653135 @default.
• W4224871294 cites W2560635244 @default.
• W4224871294 cites W2589053981 @default.
• W4224871294 cites W2737082469 @default.
• W4224871294 cites W2750328162 @default.
• W4224871294 cites W2766016994 @default.
• W4224871294 cites W2789574985 @default.
• W4224871294 cites W2801774047 @default.
• W4224871294 cites W2889873218 @default.
• W4224871294 cites W2896664662 @default.
• W4224871294 cites W2896846857 @default.
• W4224871294 cites W2899783716 @default.
• W4224871294 cites W2946663348 @default.
• W4224871294 cites W2948362628 @default.
• W4224871294 cites W2976415870 @default.
• W4224871294 cites W2980895498 @default.
• W4224871294 cites W2985960345 @default.
• W4224871294 cites W3025126564 @default.
• W4224871294 cites W3029225363 @default.
• W4224871294 cites W3085853688 @default.
• W4224871294 cites W3097624000 @default.
• W4224871294 cites W3121234767 @default.
• W4224871294 cites W3123151883 @default.
• W4224871294 cites W3133509869 @default.
• W4224871294 cites W4205376723 @default.
• W4224871294 cites W4206666777 @default.
• W4224871294 cites W4235489019 @default.
• W4224871294 doi "https://doi.org/10.1016/j.ebiom.2022.104010" @default.
• W4224871294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35477069" @default.
• W4224871294 hasPublicationYear "2022" @default.
• W4224871294 type Work @default.
• W4224871294 citedByCount "13" @default.
• W4224871294 countsByYear W42248712942022 @default.
• W4224871294 countsByYear W42248712942023 @default.
• W4224871294 crossrefType "journal-article" @default.
• W4224871294 hasAuthorship W4224871294A5019444838 @default.
• W4224871294 hasAuthorship W4224871294A5025723323 @default.
• W4224871294 hasAuthorship W4224871294A5036426179 @default.
• W4224871294 hasAuthorship W4224871294A5042989547 @default.
• W4224871294 hasAuthorship W4224871294A5058082424 @default.
• W4224871294 hasAuthorship W4224871294A5065468471 @default.
• W4224871294 hasAuthorship W4224871294A5066692929 @default.
• W4224871294 hasAuthorship W4224871294A5067780934 @default.
• W4224871294 hasAuthorship W4224871294A5069311489 @default.
• W4224871294 hasAuthorship W4224871294A5077736286 @default.
• W4224871294 hasAuthorship W4224871294A5089554789 @default.
• W4224871294 hasAuthorship W4224871294A5091286114 @default.
• W4224871294 hasBestOaLocation W42248712941 @default.
• W4224871294 hasConcept C121608353 @default.
• W4224871294 hasConcept C126322002 @default.
• W4224871294 hasConcept C137061746 @default.
• W4224871294 hasConcept C167672396 @default.
• W4224871294 hasConcept C202751555 @default.

• next